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Abbreviations 
4-HNE 4-hydroxynonenal  
AC Acrolein 
AGE Advanced glycation endproduct 
AKR Aldo-keto reductase 
ALDH Aldehyde dehydrogenase 
AmpB Amphotericin B 
ARE Antioxidant response element 
DHAP Dihydroxyacetone phosphate 
DMEM Dulbecco's modified eagle's medium 
DMSO Dimethyl sulfoxide 
FA Formaldehyde 
FCS Fetal calf serum 
GAD3P Glyceraldehyde-3-phophate 
GLO1 Glyoxalase 1 
GLO1-/- Glyoxalase 1 knock-out  
GLO2 Glyoxalase 2 
GO Glyoxal 
GPX Glutathione peroxidase 
GSH Glutathione, reduced form 
GSR Glutathione reductase 
GSSG Glutathione disulphide, oxidized form 
H2O2 Hydrogen peroxide 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HMOX1 Heme oxygenase (decycling) 1  
HOG1-MAPK high osmolarity glycerol 1/mitogen-activated protein kinase  
hpf Hours post fertilization 
HTA Hemithioacetal 
KO Knock-out 
LD 50 Median lethal dose 50% 
MDA Malondialdehyde 
MG Methylglyoxal 
MG-H1 Methylglyoxal-derived Hydroimidazolone 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NADPH Nicotinamide adenine dinucleotide phosphate 
NGM Nematode growth media 
NQO1 NADH dehydrogenase (quinone) 1 
NRF2 Nuclear factor E2-related factor 2 
PBS Phosphate buffered saline 
PBS-T Phosphate buffered saline with Tween 20 
Pen Penicillin 
PRDX Peroxiredoxin 
RAGE Receptor for AGE 
RCS Reactive carbonyl species 
RIPA Radioimmunoprecipitation assay 
ROS Reactive oxygen species 
SDS Sodium dodecyl sulfate 
SOD Superoxide dismutase 
SRXN Sulfiredoxin 
Strep Streptomycin 
T1D Type 1 diabetes 
T2D Type 2 diabetes 
TXNDR Thioredoxin reductase  
WT Wildtype 
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1. Introduction 
 
Diabetes is a major metabolic disease and a leading cause for several pathological conditions 
affecting more than 400 million people worldwide [IDF Diabetes Atlas 2017]. Globally, the numbers 
of patients suffering from diabetes and associated late complications, such as retinopathy, 
neuropathy and nephropathy are rapidly increasing. The molecular mechanisms of diabetic 
complications are still not clearly understood, leading to an inadequate treatment and therapeutic 
outcome for patients [Forbes, J.M. and Cooper, M.E. 2013].  
T1D is characterized by the impairment of insulin signalling due to the destruction of pancreatic β 
cells [Alberti, K.G. and Zimmet, P.Z. 1998]. The pathology of T2D is associated with biochemical 
aspects such as insulin resistance, hyperglycaemia and obesity [Han, T.S. and Lean, M.E. 2016]. The 
standard therapy for diabetes is the glycaemic control. However, the DCCT has shown that only 11% 
of late complications in T1D [Lind et al. 2010] are explained by increased HbA1c levels and similar 
findings are observed in T2D patients [Gerstein et al. 2008]. Therefore, it is not surprising that 
patients despite well controlled HbA1c still develop late complications such as neuropathy [Ismail-
Beigi et al. 2010]. These findings show that additional mechanisms are involved in the onset of 
diabetes and the development of late complications and that these mechanisms need to be further 
investigated.  
One of the commonly accepted theories for the development of late complications is the unifying 
theory [Brownlee, M. 2001]. The theory is based on the assumption that increased glucose uptake by 
insulin-independent cells leads to elevated intracellular glucose concentrations and subsequently to 
the accumulation of reactive oxygen species (ROS), such as superoxide (O2-), hydrogen peroxide 
(H2O2) and hydroxyl radicals (HO•). Under normal physiological conditions, antioxidative defence 
systems in form of enzymes such as NADH dehydrogenase (quinone) 1 (NQO1) [Ross, D. and Siegel, 
D. 2004], superoxide dismutase (SOD) [Pias et al. 2003], catalase [Chelikani et al. 2004], glutathione 
peroxidase [Mills, G.C. 1957] or ROS scavengers such as glutathione (GSH) [Pompella et al. 2003] or 
vitamins [Deponte, M. 2013] are responsible for the detoxification of ROS to achieve low levels of 
oxidative stress within the cell [Finkel, T. and Holbrook, N.J. 2000]. An inefficient detoxification leads 
to deleterious effects on various cell compartments due to oxidative stress [Davis, K.J.A. 1995]. 
Under conditions of high glucose flux, the polyol, hexosamine and protein kinase C pathways are 
activated and furthermore, the increase in glucose metabolism leads to the accumulation of 
advanced glycation end products (AGEs). The unifying theory presupposes an important role of high 
glucose flux on cellular dysfunction and subsequently on the development of late complications 
[Brownlee, M. 2005; Giacco, F. and Brownlee, M. 2010].  
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1.1 The reactive metabolite methylglyoxal and advanced glycation end products 
 
It has been shown that AGEs were involved in the development and progression of diseases including 
diabetes [Baynes, J.W. 2003; Yamagishi et al. 2012; Yap et al. 2012]. During glycolysis, AGEs are 
derived from reactive carbonyl species (RCSs). RCSs such as glyoxal (GO), 4-hydroxynonenal (4-HNE), 
acrolein (AC) or malondialdehyde (MDA) are formed endogenously during glycolysis, by lipid 
peroxidation and during the carbohydrate metabolism [O’Brien et al. 2005]. The major precursor of 
AGEs during glycolysis is methylglyoxal (MG), an α-oxoaldehyde. MG is formed non-enzymatically as 
a by-product of the glycolysis from the spontaneous degradation of glyceraldehyde 3-phosphate 
(GAD3P) and dihydroxyacetone phosphate (DHAP) [Phillips, S.A. and Thornalley, P.J. 1993; 
Thornalley, P.J. 2008]. It is estimated that the concentration of MG in human blood plasma are in the 
range of 100-120 nM, while cellular concentrations are in the range of 1-5 µM [Thornalley, P.J. 2008]. 
As a glycation agent, MG reacts with free amino groups on proteins to form AGEs, especially with 
arginine residues to form methylglyoxal-derived hydroimidazolones (MG-H1), the most 
physiologically relevant protein modification (›90%) regarding AGEs ubiquitously found in all body 
tissues [Rabbani, N. and Thornalley, P.J. 2012].  
Within the cell, the formation of MG and its capability to promote posttranslational modifications 
leads to damaging effects such as changes in gene transcription, cell growth arrest and apoptosis, 
modification of extracellular proteins and pro-inflammatory response through an increased binding 
of glycated plasma proteins to the receptor for AGEs (RAGE) [Bierhaus et al. 2005; Brownlee, M. 
2005; Lukic et al. 2008; Allaman et al. 2015]. Subsequently, the link between increased glycolytic flux 
and increased MG formation has been shown in patients suffering from diabetes, resulting in an 
association with late complications due to an increased AGE accumulation [Thornalley, P.J. 1988; 
Phillips, S.A. and Thornalley, P.J. 1993; Beisswenger et al. 2003; reviewed in Fleming et al. 2011]. For 
instance, in patients suffering from diabetic neuropathy, it has been shown that MG-derived AGEs in 
peripheral neurons triggered pain caused by a change in the firing pattern of the sodium-gated 
voltage channels [Bierhaus et al. 2012; Eberhardt et al. 2012].  
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1.2 The detoxification of methylglyoxal via the glyoxalase system  
 
The glyoxalase system, present in the cytosol, is considered to be the main enzyme system for the 
detoxification of MG. The system consists of two enzymes using a catalytic amount of GSH to 
catalyse the conversion of MG to D-lactate [Rabbani, N. and Thornalley, P.J. 2012]. First, MG and GSH 
form, non-enzymatically and spontaneously, a hemithioacetal (HTA). Glyoxalase 1 (GLO1) catalyses 
the isomerization of HTA to S-2-hydroxylacylglutathione. In the second step, glyoxalase 2 (GLO2) 
converts the S-2-hydroxylacylglutathione to D-lactate [Thornalley, P.J. 2003]. In the past, scientific 
research has focused mainly on the initial and rate-limiting enzyme GLO1. Its activity prevents the 
accumulation of MG and therefore the formation of MG-derived AGEs. Increased concentrations of 
MG are associated with decreased activity of GLO1 in diabetes and is linked to the development of 
late complications [Vander Jagt, D.L. 2008; Rabbani, N. and Thornalley, P.J. 2011]. The observation 
that two enzymes are essential for the detoxification of MG and the role as an anti-glycation defence, 
were already made in 1951 [Racker, E. 1951]. Therefore, GLO1 and its role in detoxification has been 
characterized in many different organisms, from Saccharomyces cerevisiae [Aronsson et al. 1978], to 
plants [Deswal R. and Sopory S. K. 1991] up to humans [Cameron et al. 1997].  
The role of glyoxalase 1 in Saccharomyces cerevisiae 
S. cerevisiae represents a simple eukaryote in which glucose metabolism, the effect of MG and the 
capacity of GLO1 has been investigated. In fact, the activity of GLO1 is one of the most important 
parameters for controlling the intracellular MG concentration in yeast [Ponces et al. 2014]. It has 
been shown that osmotic stress, such as high glucose concentrations, leads to an increased MG 
formation resulting in elevated AGE formation such as argpyrimidine [Gomes et al. 2005]. Elevated 
MG levels, either via exogenous MG stimuli or due to high glucose flux, leads to an increase of GLO1 
expression via the high osmolarity glycerol 1/mitogen-activated protein kinase (HOG1-MAPK) 
pathway [Maeta et al. 2005]. Interestingly, yeast cells lacking GLO1 are viable and even further, GLO1 
knock-out (Δglo1) yeast cells show a hormetic effect when cultured with low doses of MG and this 
enables yeast cells to deal with toxic metabolites [Zemva et al. 2017].  
The role of glyoxalase 1 in Caenorhabditis elegans 
In C. elegans, it has been shown that the activity of GLO1 is reduced with age and a decrease of GLO1 
activity lead to a drastic accumulation of MG which can be reduced by overexpressing GLO1. 
Furthermore, the mean lifespan in nematodes with a GLO1 overexpression is increased from 13.3 
days to 17.2 days, while RNAi-mediated knock-down of GLO1 decreased mean lifespan from 18 days 
to 8.6 days.  
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The overexpression of GLO1 also leads to decreased MG-derived AGEs (50%) and this accumulation is 
associated with an elevated formation of superoxide in the mitochondria [Morcos et al. 2008; 
Schlotterer et al. 2009].  
The role of glyoxalase 1 in Drosophila melanogaster 
D. melanogaster has been emerged as a useful model to study human diseases including 
neurodegenerative disease, cancer and metabolic dysfunction [Bellen, H.J. and Yamamoto, S. 2015]. 
To obtain consistent phenotypes, the group of Aurelio Teleman (German Cancer Research Center, 
Heidelberg, Germany) generated a GLO1 knock-out fly [Moraru et al. 2018]. They have reported that 
GLO1 knock-out flies are viable and normal in appearance. Endogenous MG was mildly elevated and 
complications characteristic for T2D were detected in these animals. Young GLO1 knock-out flies 
were found to be insulin resistant; they became obese and hyperglycemic during aging. This data 
would suggest that the loss of GLO1 lead to elevated MG levels and thereby to the onset of a 
diabetes-like phenotype [Moraru et al. 2018].  
The role of glyoxalase 1 in Danio rerio 
D. rerio (zebrafish) has been proven as a model organism to study vascular development, function 
and mechanisms with shared functions in mammals. Indeed, besides S. cerevisiae [Tyedmers, J. 
2012], C. elegans [Mendler et al. 2012] and D. melanogaster [Teleman et al. 2012], zebrafish has 
evolved as a model organism for investigations of metabolic disorders such as hyperglycemia-
induced pathologies [Gleeson et al. 2007; Olsen et al. 2010]. To target the role of GLO1 in zebrafish, 
the group of Jens Kroll (University Heidelberg, Medical Faculty Mannheim, Germany) generated a 
GLO1 knock-out zebrafish. The first evidence for elevated MG levels when GLO1 is impaired has been 
shown in GLO1 transient morpholino-induced knock-down animals resulting in vascular changes 
[Jörgens et al. 2015]. The GLO1 knock-out animals also showed mildly increased MG levels but no 
altered vasculature structures caused by endogenously applied MG [Lodd et al. 2018, under 
revision]. 
The role of glyoxalase 1 in mammals 
In 1998, it has been shown on bovine endothelial cells that the overexpression of GLO1 leads to the 
prevention of hyperglycemia-induced elevated MG and AGE [Shinohara et al. 1998]. Furthermore, it 
was shown that the overexpression of GLO1 prevented the impairment of angiogenesis under 
hyperglycemic conditions in human endothelial cells [Ahmed et al. 2008]. The downregulation of 
GLO1 via RNA interference results in a loss of viability in neurons [Bélanger et al. 2011] and the 
knock-down of GLO1 via small interfering RNA (45-65% reduction of GLO1 expression) leads to 
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increased MG-H1 formation in murine glomeruli and tubular cells [Giacco et al. 2014]. In vitro studies 
from 2016 in human aortic endothelial cells have shown that the knock-down of GLO1 leads to 
increased MG, enhanced inflammation markers and apoptosis which might contribute to vascular 
damage [Stratmann et al. 2016]. In mice and rats, overexpression of GLO1 in rats leads to reduced 
levels of AGEs under diabetic conditions [Brouwers et al. 2011] and to the prevention of impaired 
vascular dilatation in diabetic rats [Brouwers et al. 2010; reviewed Rabbani, N. and Thornalley, P.J. 
2012]. The impairment of GLO1 activity, by a partial reduction, leads to hyperalgesia and 
nephropathy in mice and in patients suffering from diabetes [Bierhaus et al. 2012; Giacco et al. 
2014]. Furthermore, it has been hypothesized that the activity of GLO1 correlates with diabetic 
neuropathy because it has been shown that in human blood samples from T1D and T2D patients with 
neuropathy the activity of GLO1 is reduced [Skapare et al. 2013]. Based on these findings, it has been 
hypothesized that increasing expression of GLO1 may improve metabolic health in humans. 
Therefore, a GLO1 inducer was developed which can activate GLO1 activity via a functional 
regulatory antioxidant response element (ARE), induced by the transcriptional factor nuclear factor 
E2-related factor 2 (NRF2) [Xue et al. 2015; Xue et al. 2015; Xue et al. 2016]. It was shown that the 
GLO1 inducer corrected insulin resistance, improved glycaemic control and vascular inflammation in 
healthy overweight and obese subjects [Rabbani, N. and Thornalley, P.J. 2018].  
In contrast, in 2017 has been shown that the total loss of GLO1 in murine Schwann cells did not lead 
to elevated MG and MG-H1 levels and furthermore, the total knock-out of GLO1 and its function to 
detoxify MG, was compensated by other enzymes such as aldo-keto-reductases (AKR) and aldehyde 
dehydrogenases (ALDH) [Morgenstern et al. 2017]. Additionally, a viable GLO1 knock-out mouse was 
created and showed a reduced anxiety-like and an increased depression-like behavior [Jang et al. 
2017]. A viable GLO1 knock-out mouse was generated using the CRISPR/Cas9 technique. No elevated 
MG or MG-H1 levels were found even under hyperglycemic conditions, no aggravation in 
nephropathic changes were detected and subsequently, AKR subtypes as compensatory enzymes 
were identified in kidney and liver [Schuhmacher et al. 2018].  
1.2.1 Alternative detoxification of methylglyoxal 
Even though GLO1 is the main enzyme to detoxify MG, various alternative enzymes has been 
described which are able to detoxify MG. Studies have focused on the NADP/NADPH-dependent 
subtypes of the AKR and ALDH families, which were found to convert MG into non-toxic end products 
[Vander Jagt, D.L. and Hunsaker, L.A. 2003].  
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The family of AKRs contains more than 190 subtypes and have a broad range of substrates such as 
MDA, 4-HNE, GO and MG. The AKR family consists of about 60 members which are also able to 
detoxify MG in vivo [Baba et al. 2009]. The subtypes AKR1a1, 1b1 and 1b3 are able to convert MG 
into hydroxyacetone and lactaldehyde [Vander Jagt et al. 1992; Vander Jagt, D.L. and Hunsaker, L.A. 
2003]. In vivo, AKR1b3 null mice showed an increased AGE formation in the heart and an increased 
atherosclerotic lesion formation [Baba et al. 2009]. In murine Schwann cells, AKR1b3 has been shown 
to play an essential role in the detoxification of MG [Morgenstern et al. 2017]. Both findings, in vitro 
and in vivo, confirmed the important role of AKRs as an alternative detoxification system for MG. 
Additionally, the family of ALDHs has been studied regarding the detoxification of reactive 
metabolites, such as MG. The subtypes ALDH1, 2, 3 and 9 are able to convert MG into pyruvate in 
vitro [Izaguirre et al. 1998]. When GLO1 is knocked-out, the activity of AKR1b3 is increased, 
particularly in the kidney. Additionally, there is evidence that the activity of ALDHs in the liver is also 
increased which are also known to detoxify MG in vivo [Schuhmacher et al. 2018].  
In addition, other organisms also have alternative detoxification mechanisms. It has been shown that 
the transcription factor Yap 1 is up-regulated and constitutively active in the nucleus in Δglo1 yeast 
cells and activates the expression of target genes responsible for the GSH metabolism and 
detoxification such as GSH synthesis (GSH1, GSH2) [Grant et al. 1996] and GSH-dependent 
antioxidant enzymes (GPX2) [Tsuzi et al. 2004; Maeta et al. 2004; reviewed in Inoue et al. 2011]. It 
has been shown that MG activates Gcn2 followed by the activation of Gcn4, a master regulator of 
gene expression. In Δgcn4 yeast cells, the response to MG stress was impaired indicating that Gcn4 
may play an important role, but the mechanism behind the adaptive response is still under 
investigation [Nomura et al. 2008]. Another concept of regulating MG stress is the activation of the 
yeast aldose reductase (Gre3) via the high osmolarity glycerol mitogen-activated protein kinase 
(HOG-MAPK) pathway [Aguilera, J. and Prieto, J.A. 2001]. It has been shown that the overexpression 
of Gre3 increases MG tolerance and furthermore compensates the loss of GLO1 in Δglo1 cells 
[Aguilera et al. 2005]. In C. elegans, 11 ALDH genes have been identified [Sophos et al. 2001]. Most of 
the ALDH genes were predicted to have oxidoreductase activity, but only alh-1 and alh-10 has been 
shown to moderately contribute to the oxidation of 4-HNE [Singh et al. 2008]. The substrates of the 
other enzymes are still not clear. D. melanogaster expresses various AKR genes [Davidson et al. 
1978], but the mechanisms and the physiological role of these proteins are still under investigation. 
ALDH2 is capable of the detoxification of aldehydes [Rothacker, B. and Ilg, T. 2008] with a broad 
substrate specificity, probably necessary to protect from various toxic aldehydes generated by lipid 
peroxidation or acetaldehyde accumulation [Esterbauer et al. 1991; Fry, J.D. and Saweikis, M. 2006; 
Chakraborty, M. and Fry, .JD. 2011].  
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In zebrafish, it is known that they express the AKRs 1a1a, 1a1b (members of AKR1a1) and 1b1 [Thisse 
et al. 2004] but it is still not fully understood whether these genes could compensate the function of 
GLO1 to detoxify MG.  
 
1.3 Aim of the study 
 
Over the last two decades, the role of GLO1 has been studied extensively. In S. cerevisiae and C. 
elegans, it has been shown that GLO1 is one of the most important detoxification enzymes for MG 
[Ponces et al. 2014; Zemva et al. 2017; [Morcos et al. 2008; Schlotterer et al. 2009]. In 2014, it has 
been shown that the GLO1 knock-down leads to increased MG-H1 formation in murine glomeruli and 
tubular cells [Giacco et al. 2014]. However, conflicting data regarding the detoxification of MG have 
recently been published. It has been reported that the knock-out of GLO1 does not influence the MG 
metabolism in murine Schwann cells [Morgenstern et al. 2017] and in GLO1-/- mice [Jang et al. 2017; 
Schuhmacher et al. 2018] due to alternative detoxification mechanisms.  
The contradictory findings lead to the question whether the loss of GLO1 can cause different effects 
across species. Thereby raises the question whether findings from simple organisms are transferable 
to mammals. This study aims to define possible effects of the loss of GLO1 in simple organisms such 
as S. cerevisiae and C. elegans up to zebrafish and mammals. The comparison of various model 
organisms can help to better understand the contribution of GLO1 in simple and complex organisms. 
To address this question, the MG content, the proliferation/fertilization rate and the response 
towards toxins will be analysed.  
From the previous findings in mice [Schuhmacher et al. 2018], it is known that alternative 
mechanisms could compensate the loss of GLO1 in mice with regard to the detoxification of MG. As 
these compensatory enzymes are also involved in the detoxification of other toxic substrates, the 
contribution of general protective mechanisms in vitro and in vivo will be determined.  
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2. Material and Methods 
 
2.1 Material 
 
Chemicals and reagents: (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) (MTT, Sigma, 
Steinheim, Germany); 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Sigma, Steinheim, 
Germany); 4-hydroxynonenal (4-HNE, Sigma, Steinheim, Germany); Acetaldehyde (AA, Sigma, 
Steinheim, Germany); Acrolein (AC, Sigma, Steinheim, Germany); Agar (Sigma, Steinheim, Germany); 
Amphotericin B (AmpB, Gibco, Thermo Fisher Scientific, Karlsruhe, Germany); Dimethyl sulfoxide 
(DMSO, Honeywell, New Jersey, United States); Dithiothreitol (DTT, Sigma, Steinheim, Germany); 
Dulbecco’s modified eagle’s medium (DMEM, Gibco, Thermo Fisher Scientific, Karlsruhe, Germany); 
Ethanol (Roth, Karlsruhe, Germany); Ethylenediaminetetra acetic acid (EDTA, Roth, Karlsruhe, 
Germany); Fetal calf serum (FCS, Gibco, Thermo Fisher Scientific, Karlsruhe, Germany); Formaldehyde 
(FA, Sigma, Steinheim, Germany); Glucose (Merck, Darmstadt, Germany); Glutathione (GSH, Sigma, 
Steinheim, Germany); Glycerol (Applichem, Darmstadt, Germany); Glycin (Applichem, Darmstadt, 
Germany); Hydrogenperoxide (H2O2, 37%, Sigma, Steinheim, Germany); Malondialdehyde (MDA, 
Sigma, Steinheim, Germany); Methanol (Sigma, Steinheim, Germany); Methylglyoxal (MG, 40%, 
Sigma, Steinheim, Germany); Monopotassium phosphate (Sigma, Steinheim, Germany); Nicotinamide 
adenine dinucleotide phosphate (NADPH, Sigma, Steinheim, Germany); NP 40 (Applichem, 
Darmstadt, Germany); Penicillin-streptomycin (Pen-Strep, Gibco, Thermo Fisher Scientific, Karlsruhe, 
Germany) ; Phosphate buffered saline (PBS, Sigma, Steinheim, Germany); Pierce protein-free 
blocking solution (Thermo Fisher Scientific, Karlsruhe, Germany); Protease inhibitor cocktail (PIC, 
Sigma, Steinheim, Germany); Sodium dodecyl sulfate (SDS, Roth, Karlsruhe, Germany); Sodium 
chloride (Sigma, Steinheim, Germany); Sodium hypochlorit (Roth, Karlsruhe, Germany); Sodium 
phosphate di-sodium salt (Applichem, Darmstadt, Germany); Tris (hydroxymethyl) amino methane 
(TRIS, Roth, Karlsruhe, Germany); Triton-X 100 (Applichem, Darmstadt, Germany); Trypsin-EDTA 
(0.05% Gibco, Thermo Fisher Scientific, Karlsruhe, Germany); Tween 20 (Roth, Karlsruhe, Germany); 
β-Mercaptoethanol (Merck, Darmstadt, Germany). 
Consumables and hardware: Bacto peptone (BD Bioscience, Heidelberg, Germany); Bacto yeast 
extract (BD Bioscience, Heidelberg, Germany); Biophotometer (Eppendorf, Hamburg, Germany); 
Bioruptor (Diagenode, New Jersey, United States); Cell culture clean bench (Thermo Fisher Scientific, 
Karlsruhe, Germany); Cell culture dishes (Cellstar, Greiner Bio-One, Nürtingen, Germany); Cell culture 
flasks (Cellstar, Greiner Bio-One, Nürtingen, Germany); Enhanced Chemiluminescence (ECL) Western 
Blotting Detection Reagent (GE Healthcare, Buckinghamshire, United Kingdom); FluoStar Omega 
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Multiplate Reader (BMG Labtech, Ortenberg, Germany); High Capacity cDNA Reverse Transcriptase 
Kit (Thermo Fisher Scientific, Karlsruhe, Germany); Incubator (New Brunswick, Eppendorf, Hamburg, 
Germany); Light Cycler 480 Instrument II (Roche, Mannheim, Germany); Loading dye concentrated 
(Fermentas, St. Leon-Rot, Germany); Milk powder (Roth, Karlsruhe, Germany); Mini-Protean TGX 
precast gels (4-20% acrylamide, Biorad, München, Germany); Nitrocellulose blotting membrane (GE 
Healthcare, Buckinghamshire, United Kingdom); Page-ruler pre-stained protein ladder (Fermentas, 
St. Leon-Rot, Germany); PeqGOLD Total RNA Kit (Peqlab, Erlangen, Germany); Primers (Eurofins 
Genomics, Ebersberg, Germany); Protein extraction beads (Diagenode, New Jersey, United States); 
Quanti Nova Sybr Green Kit (Qiagen, Hilden, Germany); Tandem mass spectrometry (LC-MS/MS, TQS, 
TQXS, Waters Corporation, Massachusetts, United States); Trans Blot Turbo Transfer System (Biorad, 
München, Germany); Western Blotting chamber (Biorad, München, Germany); X-ray film processor 
(Cawo Solutions, Schrobenhausen, Germany); X-ray films (GE Healthcare, Buckinghamshire, United 
Kingdom). 
 
2.1 In Vitro Methods 
 
2.2.1 Cell culture 
Cells were cultured in a humidified incubator with 5% CO₂ at 37 °C. Cells were grown to 80% 
confluence for experiments and passaged at 90% confluence using 0.05% Trypsin-EDTA (Gibco). Cell 
culture experiments were performed under sterile conditions. Immortalized murine endothelial 
cardiac (MCEC), renal tubular epithelial (M1), kidney mesangial (MES13) and Schwann cells (SW10) 
were obtained from ATCC® (Virginia, United States). For all cell types, GLO1-deficient cells (GLO1-/-) 
were generated via the CRISPR/Cas9 technique and kindly provided by Dr. Thomas Fleming and Dr. 
Jakob Morgenstern (University Hospital Heidelberg, Germany). Cells were grown in DMEM (Gibco) 
containing 1 g/mL glucose (5.5 mM) or 4.5 g/mL glucose (25 mM), 10% FCS, 1% HEPES buffer (Sigma), 
1% Pen-Strep (10,000 units/mL, 10 mg/mL, Gibco) and 1% AmpB (250 μg/mL, Gibco). 
2.2.2 Colorimetric MTT assay 
The colorimetric MTT assay was used for the determination of viability as described previously 
[Mosmann, T. 1983]. Cells were seeded in a 96-well-plate and allowed to adhere overnight at 37 °C. 
At 80% confluency, cells were treated with the specific compound and incubated in 0.1% FCS 
containing DMEM media for further 48 h at 37 °C. For cell viability determination, 50 µL of MTT 
solution (2 mg/mL in PBS) was added to the media and incubated at 37 °C for 2-3 h.  
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Reduced MTT was solubilized by adding 200 µL DMSO. The absorbance was measured at 590 nm 
using a FLUOstar OMEGA multiplate reader (BMG Labtech). Data were given in percentage and 
plotted as cell viability (%) vs. concentration. To calculate the concentration at which 50% cell 
viability (LD 50) is achieved, data were fitted by nonlinear regression using the GraphPad PRISM 7 
software (GraphPad Software Inc.). 
2.2.3 Real-time quantitative PCR 
Cells were grown in a T175 cell culture flask (Thermo Fisher Scientific) and harvested and collected as 
described previously at 90% confluency (2.2.1). For RNA extraction, the PeqGOLD Total RNA Kit 
(Peqlab) was used as described in the manufacturer protocol. 1 µg RNA was converted into cDNA 
with the High Capacity cDNA Reverse Transcriptase Kit (Thermo Fisher Scientific) according to the 
manufacturer protocol. The quantitative real-time PCR was performed with 10 µL cDNA using the 
Quanti Nova Sybr Green PCR Kit (Qiagen, 10 μl of reaction buffer contains 1 x SYBR Green Mastermix, 
200 nM forward primer, 200 nM reverse primer). The analysis was performed using a Roche 
Lightcycler 480 applying the following protocol (tbl. 1).  
 
Table 1. Thermocycler program for real-time quantitative PCR.  
 
Step Temperature [°C] Time Number of cycles 
Pre-incubation 95 7 min 1 
Amplification 
95 10 sec 
45 60 20 sec 
72 1 sec 
Melting curve 
95 5 sec 
1 65 1 min 
97 5 acquisitions per °C 
Cooling 4 ∞ 1 
 
 
Signals of amplified products were verified using melting curve analysis. The mRNA levels were 
normalized to the geometric mean of housekeeper genes. Following primer sequences were used 
(tbl. 2). 
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Table 2. Aldo-keto-reductase and aldehyde-dehydrogenase primer.  
 
Gene PrimerBank Forward primer Reverse primer 
AKR1a1 10946870a1 5’-AGCCTGGTCAGGTGAAAGC-3’ 5’-GGCCTCCCCAATCTCAGTT-3’ 
AKR1b3 31981909a1 5’-AGGCCGTGAAAGTTGCTATTG-3’ 5’-ATGCTCTTGTCATGGAACGTG-3’ 
AKR1b8 6679791a1 5’-GACCAAGGCAGAATCCTCACC-3’ 5’-AGATGCCCTTCGAGTGACAGT-3’ 
AKR1b10 31982057a1 5’-CTAGTGCCAAACCAGAGGACC-3’ 5’-TCCTGTATTCGAGAAGGTGTCA-3’ 
AKR1c14 19527294a1 5’-GTGTGGTACTAAACGATGGTCAC-3’ 5’-CAAATAAGCGGAGTCAAAATGGC-3’ 
AKR1c18 19527284a1 5’-TCGTCCAGAGTTGGTCAGAC-3’ 5’-CTTTAGGCAAAAGCTCATTCCCT-3’ 
AKR1c20 16905111a1 5’-ATCGGGGTGTGCAACTTTAAC-3’ 5’-AGCACTATGAGCAACCAAAACA-3’ 
AKR1cl 13386240a1 5’-TTGGAACAATCCCTGAGAAAGC-3’ 5’-TGGCTAACCCTGAATCCTTACA-3’ 
AKR7a5 7659728a1 5’-CGGCCAGTCCGAGAACATC-3’ 5’-TTCAGTGACTTCCCTTCCCAG-3’ 
ALDH1a1 7304881a1 5’-ATACTTGTCGGATTTAGGAGGCT-3’ 5’-GGGCCTATCTTCCAAATGAACA-3’ 
ALDH1a2 6677665a1 5’-CAGAGAGTGGGAGAGTGTTCC-3’ 5’-CACACAGAACCAAGAGAGAAGG-3’ 
ALDH1a3 31542123a1 5’-GGGTCACACTGGAGCTAGGA-3’ 5’-CTGGCCTCTTCTTGGCGAA-3’ 
ALDH1b1 21312260a1 5’-CTCCAGGGCAGGACTACCTC-3’ 5’-CATGCCACTCGTTGTTGATGA-3’ 
ALDH2 6753036a1 5’-GACGCCGTCAGCAGGAAAA-3’ 5’-CGCCAATCGGTACAACAGC-3’ 
ALDH3a1 6680676a1 5’-AATATCAGTAGCATCGTGAACCG-3’ 5’-GGAGAGCCCCTTAATCGTGAAA-3’ 
ALDH3a2 6680678a1 5’-TCTCTGCCCTTTGGAGGTGT-3’ 5’-AGCTGATCCTTGACAATCACAG-3’ 
ALDH3b1 34328288a1 5’-ATGGACTCGTTTGAAGACAAGC-3’ 5’-GATGGCAATCTCAGACACCTC-3’ 
ALDH9a1 9910128a1 5’-GGCCGAGTGATTGCCACTT-3’ 5’-AGGCCACTTTTCTTACTCCAGA-3’ 
 
 
2.2.4 Preparation of total protein extracts 
3x106 cells were harvested and collected as described previously (2.2.1). 500 µL of ice-cold radio 
immunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl pH 7.5; 150 mM NaCl; 1% TritonX-100; 
0.5% Na-deoxycholate; 0.1% SDS; fresh: 0.5 DTT; 1% PIC (Sigma) were added to each sample. After 10 
min incubation on ice, cells were sonicated at 60% power for 30 sec (3 cycles). Cells were centrifuged 
at 14,000 rpm for 10 min at 4 °C and afterwards, the supernatant was transferred into a new tube. 
Protein concentration was determined using Bradford reagent as described previously [Bradford, M. 
1976].  
2.2.5 Quantification of proteins via western blotting 
For the quantification of proteins via Western Blotting, samples with a final concentration of 1 µg/µL 
were incubated in 1x LaemmLi buffer (Sigma) for 10 min at 95 °C. Proteins were separated by a Mini-
PROTEAN TGX pre-casted gel (4–20% acrylamide, Bio-Rad) for 45 min at 180 volt. Afterwards, 
proteins were transferred to a nitrocellulose membrane for 30 min at 25 volt. 
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Membranes were blocked with 5% milk in PBS containing 0.05% Tween (PBS-T) or with Pierce 
protein-free blocking buffer for MG-H1 (Thermo Fisher Scientific) at room temperature for 1 h. 
Primary antibodies were incubated overnight at 4 °C. After washing the membranes with PBS-T, 
secondary antibodies were incubated for 1 h at room temperature. Primary and secondary 
antibodies were listed in table 2. After final washing steps with PBS-T, proteins were visualized on X-
ray films using ECL Western Blotting Detection Reagent (GE Healthcare). Exposure time depended on 
protein of interests (approx. 30 sec – 2 min). Protein expression was determined via GS-800 
calibrated densitometer and the analyzing software QuantityOne (Bio-Rad). Protein quantification 
was normalized to β-actin expression.  
 
 
Table 3. Antibodies.  
 
Antibody Isotope Dilution Company 
Primary 
anti-GLO1 rat 1: 1000 Abcam (81461) 
anti-MG-H1 rat 1:450 
Provided by Dr. T. Fleming and Dr. J. 
Morgenstern (University Hospital 
Heidelberg, Germany) in collaboration with 
the monoclonal antibody core facility at 
Helmholtz Centre Munich, Germany 
[Morgenstern et al. 2017] 
anti-ß-actin rabbit 1:1000 Cell Signalling Technology (4967) 
Secondary (HRP-linked)   
anti-Rat  2x dilution of 
primary antibody 
Cell Signalling Technology (7077) 
anti-Rabbit  Cell Signalling Technology (7074) 
 
 
2.2.6 Enzyme activity assays 
The activity of GLO1 was determined by measuring the increase of absorbance at 235 nm due to the 
formation of S-D-lactoylglutathione generated from HTA by pre-incubation of MG and GSH as 
described previously [Thornalley, P. 1988]. Cells were harvested (2.2.1) and proteins were lysed as 
described previously (2.2.4). For the assay, 10µg/10 µL protein were pipetted into a 96-well UV 
microplate and incubated with 190 µL reaction buffer (100 mM sodium phophaste buffer pH 6.6; 20 
mM GSH; 20 mM MG) at 37°C for 10 min. The absorbance at 235 nm was recorded every 30 sec for a 
period of 10 min using a FLUOStar Omega Microplate Reader (BMG Labtech).  
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The activity of AKR, ALDH and GSH reductase was determined as described previously [Srivastava et 
al. 1999; Skapare et al. 2013; Carlberg, I. & Mannervik, B. 1985] with minor changes, supported by 
Dr. Jakob Morgenstern (University Hospital Heidelberg, Germany). Briefly, AKR activity was 
determined by following the loss of NADPH (0.1 M sodium phosphate pH 7.2, 0.1–2 mM MG, 0.1 mM 
NADPH); ALDH activity was measured by the rate of NADPH formation (75 mM Tris-HCl pH 9.5, 10 
mM DL-2-amino-1-propanol, 0.5 mM NADP, 0.1–2 mM MG) both at 340 nm.  
2.2.7 Quantification of methylglyoxal and MG-derived proteins 
1x106 cells were collected as described previously (2.2.1). The determination of MG and MG-H1 via 
liquid chromatography with tandem mass spectrometry (LC-MS/MS) (TQS, TQXS, Waters®) was 
performed by the CRC1118 LC-MS/MS Core Facility (S01) by Dr. Thomas Fleming (University Hospital 
Heidelberg, Germany) as described previously [Rabbani, N. & Thornalley, P.J. 2014; Thornalley, P.J. & 
Rabbani, N. 2014]. The content of MG-H1 was determined via a stable isotope-dilution with LC-
MS/MS after an enzymatic hydrolysis as described [Thornalley et al. 2003].  
 
2.3 In vivo Methods 
2.3.1 Saccharomyces cerevisiae strains and standard growth conditions 
The S. cerevisiae strain BY4741 (Euroscarf) was used either as a control (wildtype; WT) and further to 
create a GLO1 knock-out strain (Δglo1). Both strains were kindly provided and introduced by Dr. Jens 
Tyedmers (University Hospital Heidelberg, Germany). Yeast cells were grown in Yeast 
Extract/Peptone/Dextrose (YPD) media containing 100 mM glucose (10 g Bacto Yeast Extract (BD), 20 
g Bacto Peptone (BD), 100 mM glucose for 1 L YPD) at 30 °C on a shaker (120 - 150 rpm) and spotted 
on YPD plates at 30 °C.  
2.3.2 Glyoxalase 1 activity assay in Saccharomyces cerevisiae 
To determine the activity of GLO1, 1 mL of a 50 mL cell suspension was spectrophotometrically 
measured at the wavelength of 600 nm to determine the optical density of the sample (OD600) 
(BioPhotometer, Eppendorf). When the cells reached an OD600 value of 0.3 (logarithmic growth 
phase), cells were lysed in 150 µL lysis buffer (10 mM Tris-HCl pH 7.5; 150 mM NaCl; 0.1% NP40; 0.5 
M EDTA; fresh: 10 µL/mL protease inhibitor cocktail (P9599, Sigma)). 50 mg of protein extract beads 
(Diagenode) were added to the sample and sonicated in a Bioruptor Pico Waterbath (Diagenode, 
sonication cycle 30 sec., total sonication for 30 cycles, at 4 °C).  
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The sonication was repeated in total three times. Afterwards, cells were centrifuged at 14,000 rpm 
for 15 min at 4 °C. The supernatant was transferred into a new 1.5 mL Eppendorf tube. The protein 
concentration was determined as described in 2.2.4 and the further GLO1 activity assay was 
performed as previously described in 2.2.6.  
2.3.3 Quantification of methylglyoxal and MG-derived proteins in Saccharomyces 
cerevisiae 
For the quantification of MG and MG-H1, 50 mL of cells were grown under standard growth 
conditions (see 2.3.1). At OD600 0.3, cells were harvested, lysed and sonicated (see 2.3.2). The protein 
concentration was determined by the CRC1118 LC-MS/MS Core Facility (S01) by Dr. Thomas Fleming 
(University Hospital Heidelberg, Germany) as described in 2.2.4. The quantification of MG and MG-H1 
via LC-MS/MS was performed as described in 2.2.7.  
2.3.4 Determination of proliferation rate in Saccharomyces cerevisiae 
For determination of the proliferation rate, cells were grown in YPD media (see 2.3.1) at 30 °C. 1 mL 
of the cell suspension was measured spectrophotometrically. At OD600 0.1, the OD600 was measured 
every 30 minutes until cells reached their plateau growth phase (OD600 0.8). The different time points 
were normalized to the starting OD600 value.  
2.3.5 Toxicity assay in Saccharomyces cerevisiae 
Cells were grown under standard growth conditions (see 2.3.1) to the logarithmic growth phase. At 
OD600 0.3, cells were treated with increasing concentrations either with MG, hydrogen peroxide 
(H2O2) or formaldehyde (FA). Non-treated cells served as control. Cells were incubated for 60 min at 
30 °C. Afterwards, OD600 was measured and cells were re-suspended in a new 1.5 mL Eppendorf tube 
to reach the same OD600 (reflecting the cell number) in each sample. Subsequently, cells were spotted 
onto YPD plates in a serial dilution (1:5). Plates were incubated for 48 h at 30 °C to determine cell 
survival. 
2.3.6 Caenorhabditis elegans strains and standard growth conditions 
The WT strain N2 Bristol and the GLO1 knock-out (GLO1-/-) strain VC343 [glod-4(gk189)III] were 
purchased from the Caenorhabditis Genetics Centre (University of Minnesota, USA). Both strains 
were cultured on nematode growth media (NGM) plates (for 1 L: 17 g agar, 3 g NaCl, 2.5 g peptone; 
after autoclaving 25 mL 1 M KPO4, 1 mL 1 M MgSO4, 1 mL cholesterol (50 mg/mL), 1 mL 1 M CaCl2) at 
20 °C or 25 °C. Nematodes were fed with the concentrated Escherichia coli (E.coli) strain OP50 
(provided by the Caenorhabditis Genetics Centre) in LB-media (4 g Bacto peptone, 2 g Bacto yeast 
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extract, 4 g NaCl in 400 ml water). For synchronization of same-aged nematodes, plates (60 mm 
diameter petri dishes, Greiner) containing eggs were washed in M9 buffer (for 1 L: 3 g KH2PO4, 6 g 
Na2HPO4, 5 g NaCl; after autoclaving 400 µL 2.5 M MgSO4). After collecting the pellet in a 15 mL 
falcon, nematodes were bleached for 5 min at room temperature in bleaching solution (3.3 mL 
sodium hypochlorit solution (Sigma), 12.5 mL 2 M NaOH (Sigma), 9.5 mL water). The pellet was 
washed three times in M9 buffer and centrifuged for 3 min at 1700 rpm. Afterwards, the eggs were 
transferred onto new NGM plates covered with OP50. After 12-14 h nematodes in the same age 
were hatched (L1 larvae). After additional 40-48 h, the nematodes were grown up to L4 larval/young 
adult stage at 20 °C.  
2.3.7 Glyoxalase 1 activity assay in Caenorhabditis elegans 
For the determination of GLO1 activity, 10 plates (60 mm diameter, Greiner) completely covered 
with a heterogeneous population of nematodes were collected in M9 buffer (2.3.6). Nematodes 
were lysed in 150 µL lysis buffer (20 mM Tris-HCl pH 8.0; 137 mM NaCl; 1% Triton-X 100; 2 mM EDTA; 
fresh: 10 µL/mL protease inhibitor cocktail (P9599, Sigma)). After adding the lysate buffer, the 
procedure for sonication, protein concentration and GLO1 activity measurement was followed as 
described in 2.3.2.  
2.3.8 Quantification of methylglyoxal and MG-derived proteins in Caenorhabditis elegans 
The quantification of MG and MG-H1 via LC-MS/MS was performed as described in 2.2.7 by the 
CRC1118 LC-MS/MS Cora Facility (S01) by Dr. Thomas Fleming (University Hospital Heidelberg, 
Germany). For the determination, 20,000 nematodes were collected in M9 buffer as described in 
2.3.7.  
2.3.9 Determination of egg laying rate in Caenorhabditis elegans 
The determination of the egg laying rate was performed with nematodes in the age of young adults. 
Five adult nematodes were transferred onto new NGM plates with OP50 and incubated for 24 h at 20 
°C. After the incubation time, the eggs were counted under a microscope.  
2.3.10 Toxicity assay in Caenorhabditis elegans 
The toxicity assay was performed with L4 larvae’s in a sterile 96-well plate (Greiner). Eight 
nematodes were transferred into each well containing 50 µL M9 buffer. The 96-well plate was 
incubated for 30 min at 20 °C. Dead nematodes were replaced before starting the experiment for a 
total number of eight nematodes per well. Nematodes in each well were counted (time point before 
toxin treatment) and afterwards treated with increasing concentrations of MG, H2O2 or FA.  
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Non-treated cells served as control. Cells were incubated at 20 °C for 2 h (MG), 20 min (H2O2) or 1 h 
(FA). After incubation, living nematodes were counted and percentage of survival was calculated.  
2.3.11 Toxicity assay in Danio rerio 
WT and GLO1 knock-out (GLO1-/-) zebrafish embryos were kindly provided at the age of 48 hours post 
fertilization (hpf) by Prof. Dr. Jens Kroll (CRC1118, B01, University Heidelberg, Medical Faculty 
Mannheim, Germany). 20 embryos per condition were transferred into new plates (60 mm diameter, 
Greiner) and treated with 10 mL of increasing concentrations of MG, H2O2 or FA (toxins were diluted 
in cleared egg water). Non-treated embryos served as control. Embryos were incubated at 28.5 °C for 
1 h (MG), 2 h (H2O2) or 1 h (FA). After incubation, living embryos were counted and percentage of 
survival was calculated. 
2.3.12 Mouse strains and standard conditions 
WT (C57BL/6) mice were purchased from Charles River Laboratories (Wilmington, Massachusetts, 
USA). GLO1 knock-out (GLO1-/-) mice were generated via CRISPR/Cas9 technique and kindly provided 
by Prof. Marc Freichel and Dr. Dagmar Schuhmacher (CRC1118, S03N, University Heidelberg, Institute 
of Pharmacology, Germany) [Schuhmacher et al. 2018]. Mice were maintained under standard 
laboratory conditions: constant temperature (22 ± 2 °C) and humidity (55 ± 5%), 12 h light/12 h dark 
cycle and free access to food and water. Animal studies were approved by the Animal Care and Use 
Committee by the regional authority in Karlsruhe, Germany (G295/15). Mice were sacrificed by CO2 
inhalation and directly perfused through the heart with ice cold PBS. For analysis, organs (heart, liver, 
kidney, muscle and brain) were dissected and flash-frozen in liquid nitrogen for direct analysis or 
storage at -80 °C.  
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2.3.13 Real-time quantitative PCR in tissue 
The flash-frozen tissue was pulverized using an ice-cold mortar and 10 mg were used for further RNA 
extraction, cDNA synthesis and Real-Time PCR as described in 2.2.3. Primer sequences were used as 
followed (tbl. 4). 
 
Table 4. Primer sequences for antioxidant genes. 
 
Gene PrimerBank Forward primer Reverse primer 
Catalase 157951740c1 5’-GGAGGCGGGAACCCAATAG-3’ 5’-GTGTGCCATCTCGTCAGTGAA-3’ 
GPX1 6680075a1 5’-AGTCCACCGTGTATGCCTTCT-3’ 5’-AGTCCACCGTGTATGCCTTCT-3’ 
GPX4 22022299a1 5’-GATGGAGCCCATTCCTGAACC-3’ 5’-GATGGAGCCCATTCCTGAACC-3’ 
GSR 34328489a1 5’-GACACCTCTTCCTTCGACTACC-3’ 5’-GACACCTCTTCCTTCGACTACC-3’ 
HMOX1 6754212a1 5’-AAGCCGAGAATGCTGAGTTCA-3’ 5’-AAGCCGAGAATGCTGAGTTCA-3’ 
NQO1 6679080a1 5’-AGGATGGGAGGTACTCGAATC-3’ 5’-AGGCGTCCTTCCTTATATGCTA-3’ 
PRDX1 6754976a1 5’-AATGCAAAAATTGGGTATCCTG-3’ 5’-AATGCAAAAATTGGGTATCCTG-3’ 
PRDX6 6671549a1 5’-CGCCAGAGTTTGCCAAGAG-3’ 5’-CGCCAGAGTTTGCCAAGAG-3’ 
SOD1 12805215a1 5’-AACCAGTTGTGTTGTCAGGAC-3’ 5’-AACCAGTTGTGTTGTCAGGAC-3’ 
SOD2 31980762a1 5’-CAGACCTGCCTTACGACTATGG-3’ 5’-CAGACCTGCCTTACGACTATGG-3’ 
SRXN1 21313268a1 5’-CCCAGGGTGGCGACTACTA-3’ 5’-CCCAGGGTGGCGACTACTA-3’ 
TXNDR1 12658437a1 5’-CCCACTTGCCCCAACTGTT-3’ 5’-CCCACTTGCCCCAACTGTT-3’ 
 
 
 
 
 
 
   
2.4 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software Inc.) and are 
expressed as mean values ± S.D. Statistical significance was analysed using two-tailed unpaired t test 
with Welch’s correction or one- or two-way ANOVA (comparison of more than one group). 
Differences were considered significant at: p›0.05 n.s.; p‹0.0001***, p‹0.001**, p‹0.05*. 
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3. Results 
 
3.1 The total loss of glyoxalase 1 leads to an increased sensitivity towards toxins 
in Saccharomyces cerevisiae 
 
GLO1-deficient (Δglo1) and wildtype (WT) yeast cells used in this work were kindly provided by Dr. 
Jens Tyedmers (University Hospital Heidelberg, Germany). To characterize Δglo1 yeast cells, the 
activity of GLO1 and the proliferation rate under basal conditions were determined. The activity of 
GLO1 was significantly reduced in Δglo1 cells as compared to WT (fig. 1 A).  
Furthermore, the proliferation rate of Δglo1 cells was significantly decreased (fig. 1 B). Regarding the 
detoxification capacities, MG and MG-H1 were determined under basal conditions. The 
measurement of MG and MG-H1 content via LC-MS/MS was performed by Dr. Thomas Fleming (LC-
MS-MS Core Facility, CRC1118, S01, University Hospital Heidelberg, Germany). The KO of GLO1 led to 
increased MG (fig. 1 C) and MG-H1 (fig. 1 D) formation. Additionally, cross-toxicity studies were 
performed. Cells were treated either with MG, H2O2 or FA and spotted in serial dilutions (1:5). For all 
three toxins, Δglo1 cells were more sensitive as compared to WT cells. The LD 50 for MG in Δglo1 
cells was 20 mM (fig. 1 E, left), for H2O2 3 mM (fig. 1 E, middle) and for FA 17.5-20 mM (fig. 1 E, left). 
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Figure 1. Effect of the total loss of glyoxalase 1 in Saccharomyces cerevisiae. White bars/dots representing wildtype (WT) 
and black bars/squares GLO1-deficient (Δglo1) yeast cells. A: GLO1 activity under basal conditions (100 mM glucose). B: 
Proliferation rate was determined via the optical density (OD600). C and D: Intracellular methylglyoxal (C) and MG-modified 
arginine residues (MG-H1) (D) levels under basal conditions (100 mM glucose) measured via LC-MS/MS. E: Effect of 
methylglyoxal (0-30 mM), hydrogen peroxide (0-6 mM) and formaldehyde (0-20 mM). Cells were treated for 1 h. Data 
represent the mean of at least three individual experiments ± S.D. P-values indicating significant changes in comparison to 
wildtype cells (p‹0.0001***, p‹0.001**, p‹0.05*). 
 
 
3.2 Increased toxin sensitivity in glyoxalase 1 deficient Caenorhabditis elegans 
 
WT (N2 Bristol) and GLO1-/- (VC343 [glod-4(gk189)III] nematodes used in this work were provided by 
the Caenorhabditis Genetics Centre (University of Minnesota, USA). Reduced GLO activity in GLO1-/- 
nematodes was validated (fig. 2 A). Furthermore, adult GLO1-/- nematodes showed a significantly 
decreased egg laying rate (fig. 2 B) as compared to their WT counterparts. The loss of GLO1 in 
nematodes was accompanied with an increased MG (fig. 2 C) and MG-H1 (fig. 2 D) formation under 
basal conditions.  
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The measurement of MG and MG-H1 content via LC-MS/MS was performed by Dr. Thomas Fleming 
(LC-MS-MS Core Facility, CRC1118, S01, University Hospital Heidelberg, Germany). To determine the 
toxic effect of MG, H2O2 and FA, the LD 50 was calculated (fig. 2E). GLO1-/- nematodes were 
significantly more sensitive to MG (35.7 vs. 20.7 mM), H2O2 (1.2 vs. 0.3 mM) and FA (26.2 vs. 7.6) 
compared to WT nematodes.  
 
 
 
 
Figure 2. Effect of the total loss of glyoxalase 1 in Caenorhabditis elegans. White bars representing wildtype (WT); black 
bars GLO1-deficient (GLO1-/-) nematodes. A: GLO1 activity in L4-stage nematodes. B: For egg laying rate, eggs from young 
adults were counted 24 h after seeding. C and D: Intracellular methylglyoxal (C) and MG-modified arginine residues (MG-
H1) (D) levels measured via LC-MS/MS. E: Lethal dose 50 (LD 50) value of methylglyoxal (MG), hydrogen peroxide (H2O2) 
and formaldehyde (FA) in L4-stage nematodes. Nematodes were treated for 2 h (MG), 20 min (H2O2) or 1 h (FA). Values 
above the bars representing the lethal dose 50 (LD 50) value [mM]. Data represent the mean of at least three individual 
experiments ± S.D. P-values indicating significant changes in comparison to wildtype nematodes (p‹0.0001***, p‹0.001**, 
p‹0.05*). 
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3.3 Total loss of glyoxalase 1 leads to a decreased sensitivity in zebrafish 
 
WT and GLO1-/- zebrafish embryos were kindly provided at the age of 48 hours post fertilization (hpf) 
by Prof. Dr. Jens Kroll (CRC1118, B01, University Heidelberg, Medical Faculty Mannheim, Germany). 
GLO1-/- zebrafish showed a decreased sensitivity to MG, H2O2 and FA (fig. 3). The effect was strong 
for FA (7.7 vs. 39.6 mM), sufficient for MG (9.5 vs. 15.0 mM) and weak for H2O2 (63.1 vs. 74.1 mM).  
 
 
 
 
Figure 3. Total loss of glyoxalase 1 leads to decreased sensitivity in zebrafish. White bars representing wildtype (WT) and 
black bars GLO1-deficient (GLO1-/-) animals. Lethal dose 50 (LD 50) value of methylglyoxal (MG), hydrogen peroxide (H2O2) 
and formaldehyde (FA) in 48 hpf old embryos. Zebrafish were treated for 1 h (MG), 2 h (H2O2) or 1 h (FA). Values above the 
bars representing the LD 50 value [mM]. Data represent the mean of at least three individual experiments ± S.D. P-values 
indicating significant changes in comparison to wildtype nematodes (p‹0.0001***, p‹0.001**, p‹0.05*). 
 
 
3.4 Total loss of glyoxalase 1 leads to an increased tolerance in mammal cells 
 
To investigate the consequences of the loss of GLO1 in mammal cells, three murine cell lines with a 
full knock-out of GLO1 were used (GLO1-/-). In all cell lines, the activity and protein content of GLO1, 
levels of MG and MG-H1 and their response to toxins and UV-C radiation were determined. MG and 
MG-H1 content was measured via LC-MS/MS by Dr. Thomas Fleming (LC-MS/MS Core Facility, 
CRC1118, S01, University Hospital Heidelberg, Germany). GLO1 activity and protein content in renal 
tubular GLO1-/- cells were significantly reduced (fig. 4 A). There was no elevation in MG (fig. 4 B) or 
MG-H1 (fig. 4 C) in the GLO1-/- renal tubular cells neither under basal (5 mM glucose) nor under 
hyperglycaemic conditions (25 mM glucose). When treated with other toxins or UV-C radiation, 
GLO1-/- renal tubular cells were more tolerant in a toxin-specific manner.  
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GLO1-/- cells treated with FA, UV-C, 4-hydroxynonenal (4-HNE) and H2O2 showed the highest increase 
regarding the LD 50 compared to WT cells. The effects for acetaldehyde (AA), acrolein (AC) or MG 
were moderate or lower to WT cells (fig. 4 D).  
 
 
 
 
Figure 4. Loss of glyoxalase 1 leads to increased tolerance in renal tubular cells. White bars representing wildtype (WT) 
and black bars GLO1-deficient (GLO1-/-) renal tubular cells. A: GLO1 activity and protein content (probed with anti-GLO1 and 
β-actin antibody). B: Intracellular methylglyoxal levels under basal (5 mM, right bars) and hyperglycaemic (25 mM, left bars) 
conditions measured via LC-MS/MS. C: Intracellular levels of MG-modified arginine residues (MG-H1) under basal (5mM, 
right bars) and hyperglycaemic (25 mM, left bars) conditions measured via LC-MS/MS. D: Lethal dose 50 (LD 50) [%] of 
GLO1-/- cells compared to wildtype cells (100 %, black line). Cells were treated for 48 h (formaldehyde, FA; UV-C; 4-
hydroxynonenal, 4-HNE; hydrogen peroxide, H2O2; acetaldehyde, AA; acrolein, AC; methylglyoxal, MG). Toxicity was 
determined via MTT assay. Data represent the mean of at least three individual experiments ± S.D. P-values indicating 
significant changes in comparison to wildtype cells (p‹0.0001***, p‹0.001**, p‹0.05*). 
 
 
Comparable results were detected in cardiac endothelial cells (fig. 5 A-C). GLO1-/- endothelial cells 
were significantly more tolerant to UV-C, H2O2 and AC (fig. 5 D). In GLO1-/- neuronal cells, GLO1 
activity was significantly reduced (fig. 6 A). For MG and MG-H1 content, there were no differences 
compared to neuronal WT cells (fig. 6 B-C). Furthermore, in those cells, the tolerance towards UV-C, 
4-HNE, H2O2 and AC was increased (fig. 6 D) 
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Figure 5. Loss of glyoxalase 1 leads to increased tolerance in endothelial cells. White bars representing wildtype (WT) and 
black bars GLO1-deficient (GLO1-/-) cardiac endothelial cells. A: GLO1 activity and protein content (probed with anti-GLO1 
and β-actin antibody). B: Intracellular methylglyoxal levels under basal (5 mM, right bars) and hyperglycaemic (25 mM, left 
bars) conditions measured via LC-MS/MS. C: Intracellular levels of MG-modified arginine residues (MG-H1) under basal 
(5mM, right bars) and hyperglycaemic (25 mM, left bars) conditions measured via LC-MS/MS. D: Lethal dose 50 (LD 50) [%] 
of GLO1-/- cells compared to wildtype cells (100 %, black line). Cells were treated for 48 h (formaldehyde, FA; UV-C; 4-
hydroxynonenal, 4-HNE; hydrogen peroxide, H2O2; acetaldehyde, AA; acrolein, AC; methylglyoxal, MG). Toxicty was 
determined via MTT assay. Data represent the mean of at least three individual experiments ± S.D. P-values indicating 
significant changes in comparison to wildtype cells (p‹0.0001***, p‹0.001**, p‹0.05*).  
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Figure 6. Loss of glyoxalase 1 leads to increased tolerance in neuronal cells. White bars representing wildtype (WT) and 
black bars GLO1-deficient (GLO1-/-) neuronal Schwann cells. A: GLO1 activity and protein content (probed with anti-GLO1 
and β-actin antibody). B: Intracellular methylglyoxal levels under basal (5 mM, right bars) and hyperglycaemic (25 mM, left 
bars) conditions measured via LC-MS/MS. C: Intracellular levels of MG-modified arginine residues (MG-H1) under basal 
(5mM, right bars) and hyperglycaemic (25 mM, left bars) conditions measured via LC-MS/MS. D: Lethal dose 50 (LD 50) [%] 
of GLO1-/- cells compared to wildtype cells (100 %, black line). Cells were treated for 48 h (formaldehyde, FA; UV-C; 4-
hydroxynonenal, 4-HNE; hydrogen peroxide, H2O2; acetaldehyde, AA; acrolein, AC; methylglyoxal, MG). Toxicty was 
determined via MTT assay. Data represent the mean of at least three individual experiments ± S.D. P-values indicating 
significant changes in comparison to wildtype cells (p‹0.0001***, p‹0.001**, p‹0.05*). 
 
 
3.5 Determination of alternative detoxification pathways in mammal cells 
 
The mRNA content of various oxidoreductase subtypes was measured. In GLO1-/- renal tubular cells, 
the AKR subtypes 1b3, 1b8, 1c14, 1c18 and the ALDH subtypes 1a1 and 9a1 were up-regulated 
compared to WT cells (fig. 7 A). The loss of GLO1 in endothelial cells led to a significantly elevated 
expression of AKR 1a1, 1c14 and 1c20 and ALDH3a2 (fig. 7 B). In GLO1-/- neuronal cells AKR subtypes 
1a1, 1b3, 7a5, 1cl, ALDH 1a2, 3a1, 1b1 and 9a1 were up-regulated compared to WT cells (fig. 7 C).  
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Figure 7. Loss of glyoxalase 1 leads to an up-regulation of oxidoreductases in mammal cells. Fold change (% of WT vs. 
GLO1-/-) of mRNA expression of different subtypes of AKRs and ALDHs in GLO1-/- mammal cells (black bars). A: Renal tubular 
cells. B: Cardiac Endothelial cells. C: Neuronal cells (Schwann cells). Values for wildtype cells are standardized to 100% 
(black line). Expression data are normalized to ß-actin. Data represent the mean of at least three individual experiments ± 
S.D. P-values indicating significant changes in comparison to wildtype cells (p‹0.0001***, p‹0.001**, p‹0.05*). 
 
 
In GLO1-/- mammal cells, an increased tolerance towards various toxic substances were found (see 
fig. 4, 5 and 6 D). To determine whether the up-regulated AKR and ALDH subtypes in renal tubular, 
endothelial and neuronal cells able to detoxify other toxic substances, activity assays with different 
substrates and co-factors were performed supported by Dr. Jakob Morgenstern (University Hospital 
Heidelberg, Germany). In GLO1-/- renal tubular, endothelial and neuronal cells, AKR enzymes revealed 
an increased activity towards FA (only moderate in renal tubular cells) and 4-HNE as substrates (fig. 8 
A, black bars). The activity of ALDH enzymes were increased towards the substrates AC (only 
moderate in renal tubular cells), 4-HNE and MDA (fig. 8 B, black bars). Additionally, two essential 
enzymes in the GSH metabolism (GSH reductase, peroxidase) showed a significant increased activity 
in the absence of GLO1 (fig. 8 C).  
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Figure 8. Increased enzyme activity in GLO1-/- mammal cells. Enzyme activity in wildtype (white bars) and GLO1-/- mammal 
cells (black bars) towards various substrates (formaldehyde, FA; 4-hydroxynonenal, 4-HNE; acrolein, AC; malondialdehyde, 
MDA; glutathione, GSH). A: Aldo-keto-reductase (AKR) activity. B: Aldehyde-dehydrogenase (ALDH) activity. C: Glutathione 
(GSH) reductase and GSH peroxidase activity. Data represent the mean of at least three individual experiments ± S.D. P-
values indicating significant changes in comparison to wildtype cells (p‹0.0001***, p‹0.001**, p‹0.05*). 
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3.6 Loss of glyoxalase 1 leads to up-regulation of protective enzymes 
corresponding to increased natural survival in mice 
 
The loss of GLO1 lead to enhanced tolerance towards various toxins and UV-C radiation, an up-
regulation of oxidoreductases correlating with an increased activity towards different substrates in 
mammal cells.  
GLO1-/- mice were kindly provided by Prof. Dr Marc Freichel (University Heidelberg, Pharmacology, 
Germany) [Schuhmacher et al. 2018]. To investigate potential defence mechanism in vivo, the mRNA 
content was screened for antioxidant enzymes. Several enzymes involved in the defence against free 
radicals were increased in the liver of GLO1-/- mice: Peroxiredoxin 6 (PRDX6), Glutathione reductase 
(GSR), NAD(P)H dehydrogenase (quinone) 1 (NQO1), Superoxide dismutase 2 (SOD2), Catalase and 
Heme oxygenase (decycling) 1 (HMOX1) (fig. 9 A, black bars). These findings in mice were linked to an 
increased natural survival rate in GLO1-/- mice (fig. 9 B) when compared to their WT counterparts.  
 
 
 
Figure 9. Loss of glyoxalase 1 correlates with increased defence and survival in mice. A: Fold change (WT vs. GLO1-/-) of 
mRNA expression of different antioxidant enzymes in liver from 6 month old GLO1-/- mice (black bars). Values for wildtype 
mice are standardized to 100% (black line). Peroxiredoxin 6, PRDX6; Glutathione reductase, GSR; NAD(P)H dehydrogenase 
(quinone) 1, NQO1; Superoxide dismutase 2, SOD2; Catalase and Heme oxygenase (decycling) 1, HMOX1. B: Natural survival 
of wildtype and GLO1-/- mice (n=13-18). Data represent the mean of at least three individual experiments ± S.D. P-values 
indicating significant changes in comparison to wildtype cells (p‹0.0001***, p‹0.001**, p‹0.05*). 
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4. Discussion 
 
4.1 The contribution of glyoxalase 1 decreases in complex organisms 
 
This study has demonstrated the decreasing dependency for GLO1 as the main detoxification system 
for MG from simple organisms up to mammals. In summary, in S. cerevisiae and C. elegans, the total 
loss of GLO1 leads to increased MG and MG-H1 levels, a decreased proliferation or fertilization rate 
and an increased sensitivity towards toxins. In zebrafish, the total loss of GLO1 resulted in a 
decreased sensitivity towards toxins. In GLO1-deficient murine cell lines, no increased MG and MG-
H1 levels under basal or hyperglycaemic conditions were determined and surprisingly, an increased 
tolerance towards toxins was detected. 
Our studies in S. cerevisiae and C. elegans showed that they cannot detoxify MG effectively when 
GLO1 is absent, resulting in an intracellular accumulation of MG and MG-H1. Zemva et al. (2017) 
showed that with increasing MG concentrations cell survival decreases in WT and even more in Δglo1 
yeast cells. This leads to the presumption that increased MG could be the possible driver for the 
decreased proliferation rate shown in our study. In C. elegans, Morcos et al. (2009) showed that in 
GLO1 knock-down nematodes elevated MG-H1 correlated with a decreased lifespan. The decreased 
lifespan could result in a shorter fertile phase which could be responsible for the decreased egg 
production in GLO1-/- nematodes shown in our study. Further studies are required to determine 
whether the fertile phase is impaired in GLO1-/- nematodes compared to WT. Another explanation for 
the decreased fertilization shown in this study could be the rescue mechanism of C. elegans. It is 
known that C. elegans enters a stage of arrested development in which the development and the 
reproduction stops due to unfavourable conditions [Golden, J.W. and Riddle, D.L. 1984; reviewed in 
Androwski et al. 2017]. It is not known yet whether MG is a possible stressor to induce a dauer stage. 
Therefore, a definite conclusion is not possible. Further studies are required to better understand 
whether the impaired fertilization is a consequence of the shorter lifespan or the dauer stage. Both 
events could possibly triggered by an elevated MG content in the GLO1-/- nematodes. Furthermore, a 
direct damaging effect of MG or an unknown consequence of the loss of GLO1 cannot be ruled out. 
The determination of the egg laying rate when treated with MG could help to address this question.  
Besides of the accumulation of MG, this study shows that the loss of GLO1 leads to an increased 
sensitivity in S. cerevisiae and C. elegans towards exogenously added MG as compared to WT. 
Alternative detoxification of MG in S. cerevisiae could be substituted by Yap 1 [Grant et al. 1996; 
Maeta et al. 2004; Tsuzi et al. 2004; reviewed in Inoue et al. 2011], Gcn2 and Gcn4 [Nomura et al. 
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2008] or the yeast aldose reductase (Gre3) via the HOG1-MAPK [Aguilera, J. and Prieto, J.A. 2001; 
Aguilera et al. 2005]. For C. elegans, less is known about alternative detoxification of MG. It is known 
that a few ALDH genes have been identified and that most of them are predicted to have 
oxidoreductase activity but whether the ALDH genes could alternatively detoxify MG is still 
investigated. Nevertheless, our data indicates that the alternative detoxification mechanisms are not 
effective as compared to GLO1 in the detoxification of MG. Furthermore, both organisms showed an 
increased sensitivity towards endogenously added H2O2 or FA, implicating that in the absence of 
GLO1 other detoxification systems are also impaired. More investigations are required to address the 
mechanisms behind the sensitive response towards other toxins. So far, it seems that simple 
organisms are more dependent on GLO1 as a defence system, not only for MG but also for other 
toxins.  
This study also showed a decreased sensitivity towards toxins in the GLO1-/- zebrafish as compared to 
WT. Lodd et al. (2018, under revision) showed only moderately elevated MG levels in GLO1-/- 
zebrafish. One explanation for the only mildly elevated MG and the decreased sensitivity could be 
possibly the up-regulation of AKR1a1a, 1a1b or 1b1 which can alternatively detoxify MG even the 
detoxification is not effective as through GLO1. Furthermore, the up-regulation of AKRs/ALDHs could 
have a positive side effect on the detoxification of H2O2 or FA resulting in a tolerance towards these 
toxins. To investigate which compensatory enzymes are activated and leading to an alternative 
defence mechanism towards stress, further studies regarding the double knock-out of AKR/ALDH and 
GLO1 in zebrafish would be helpful. In addition, Moraru et al. (2018) showed that MG and MG-H1 
were mildly elevated in GLO1-/- flies and they tolerate H2O2-induced oxidative stress better than WT 
flies similar to the findings in zebrafish. One would expect that GLO1-/- flies with elevated MG levels 
show a reduced lifespan as observed in C. elegans. Surprisingly, GLO1-/- flies show a prolonged 
lifespan. An explanation for this could be the up-regulation of alternative detoxification mechanisms 
in GLO1-/- flies. At that time, only ALDH2 is known for its capacity to detoxify aldehydes [Rothacker, B. 
and Ilg, T. 2008] but nothing is known about the specific capacity to detoxify MG in the absence of 
GLO1. Further analyses are required to determine possible alternative detoxification enzymes in 
GLO1-/- flies. 
In summary, our toxicity data in GLO1-/- zebrafish and the findings shown in GLO1-/- flies from Moraru 
et al. (2018) would suggest that there is no loss of defence in the absence of GLO1 probably due to 
alternative detoxification mechanisms. It must be noted, that to confirm these findings, further 
studies are required with zebrafish. Because of the low number of eggs, the experiment needs to be 
repeated with an increased number.  
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Furthermore, these studies were performed in 48 hpf young embryos, therefore the study should be 
repeated in adult zebrafish, in which the alternative detoxification capacity could be changed.  
In GLO1-/- murine cells, this study demonstrated that MG or MG-H1 is not elevated under basal or 
hyperglycaemic conditions. This is consistent with the data from Morgenstern et al. (2017) in murine 
Schwann cells. Here, it is important to mention that there are discrepancies when compared with 
previous studies in GLO1 knock-down mice. Giacco et al. (2014) showed an increased MG-H1 content 
in non-diabetic GLO1 knock-down mice. However, these mice still had a residual GLO1 activity left 
while our GLO1 knock-out murine cell lines and the GLO1-/- mice from Schumacher et al. (2018) 
showed no GLO1 activity. This would suggest that silencing of GLO1 is not sufficient for the up-
regulation of alternative detoxification mechanisms and that only a total loss of GLO1 leads to an 
effective compensation due to the up-regulation of alternative detoxification mechanisms. To verify 
this, alternative detoxification mechanisms in GLO1 knock-down mice should be investigated.  
 
4.2 Up-regulation of protective mechanisms corresponds to increased natural 
survival in the absence of glyoxalase 1 in a mouse model 
 
Our study shows that the loss of GLO1 leads to an increased tolerance towards a broad range of 
toxins as well as UV-C radiation in murine cell lines. The tolerance induction by the loss of GLO1 was 
cell- and toxin-specific as well as being more pronounced than in either D. melanogaster or zebrafish. 
This leads to the assumption that the loss of GLO1 induces a tolerance towards toxins. One 
explanation for the tolerance induction is the up-regulation of various AKRs and ALDHs in the GLO1-/- 
murine cell lines as shown in this study. And that these enzymes are able to detoxify a broad range of 
toxins.  
Additionally to the up-regulation of alternative detoxification enzymes resulting from the loss of 
GLO1, this study shows that the GSH reductase and GSH peroxidase are also up-regulated in the 
GLO1-/- murine cells. This indicates that the cells handle cellular stress not only by the up-regulation 
of alternative detoxification enzymes, but also by increasing their defence capacities. This is 
consistent with data from GLO1-/- flies where the GSH/GSSG ratio is increased and the animals 
tolerate H2O2 treatment [Moraru et al. 2018]. One could suggest that changes in the GSH/GSSG ratio 
were caused probably due to the loss of GLO1 and that this would be a beneficial effect for the cells 
to handle MG-independent stress.  
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Additionally, our study shows that not only GSH metabolism enzymes are up-regulated but also the 
activity of AKRs and ALDHs towards different reactive aldehydes is increased. This would confirm the 
hypothesis of an increased defence cascade in complex organisms when GLO1 is absent. The in vitro 
data are in line with our studies in GLO1-/- mice, where in the liver an increased expression of AKR1a1 
and antioxidant enzymes (NQO1, SOD2, Catalase and GSH reductase) was observed. It is to mention 
that only the expression in liver was determined. As it is known from the study of Schuhmacher et al. 
(2018), differences between tissues regarding the expression of AKRs and ALDHs were observed in 
GLO1-/- mice. Therefore, a variety of tissues needs to be further analysed to establish tissue or even 
cell-specific responses to the loss of GLO1. It is to mention that the mice in this study were at the age 
of 6 month. It would be interesting to determine the antioxidative capacity during aging to establish 
whether there are changes. Interestingly, an increased natural survival of the GLO1-/- mice were 
observed. This phenomenon could correlate with the increased up-regulation of protective enzymes. 
This finding could be confirmed by the increased lifespan observed in GLO1-/- flies [Moraru et al. 
2018]. In fact, further investigations need to be done to understand the molecular mechanism 
behind the increased longevity, but it is conceivable that the described mechanisms could be mainly 
responsible for the increased natural survival.  
With regard to the role of GLO1 in humans, the literature provides conflicting data regarding the 
activity of GLO1 in diabetic patients. In 1994, it has been shown that red blood cells from diabetic 
patients with complications have an increased GLO1 activity [McLellan et al. 1994]. In contrast, 2013 
it has been shown that in human blood samples from T1D and T2D patients with neuropathy the 
activity of GLO1 is reduced [Skapare et al. 2013]. Interestingly, Schumacher et al. (2018) revealed 
that there is evidence for an AKR-dependent MG detoxification in erythrocytes of T2D patients 
without nephropathy but not for patients with nephropathy. They suggest that diabetic patients 
without late complications are protected due to alternative detoxification mechanisms. Therefore, it 
is of high interest to investigate possible antioxidative capacities in diabetic patients with and 
without complications and to determine whether this antioxidative capacity could be useful in 
respect to develop new approaches for treating late complications.  
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Figure 10. Regulation of toxic metabolites increases during evolution in the absence of Glyoxalase 1.  
 
In conclusion, this study showed that in simple organisms, GLO1 is the main detoxification enzyme 
for MG and even though potential alternative detoxification mechanisms are present, they are not 
equivalent to the GLO1 system. Admittedly, it has been shown by Zemva et al. (2017) that low levels 
of MG have beneficial effects in S. cerevisiae, but apparently the accumulation of MG due to the loss 
of GLO1, exceeds this level. Furthermore, the loss of GLO1 does also affect the detoxification of other 
toxins. In zebrafish and D. melanogaster alternative detoxification mechanisms are able to detoxify 
most of the MG and these organisms showed a tolerance towards selected toxins. This might be a 
beneficial side effect of the up-regulation of alternative detoxification mechanisms. This is in line 
with the findings in GLO1-/- murine cell lines and mice, showing an up-regulation of alternative 
detoxification mechanisms as well as additional antioxidative capacities. This suggests that the 
alternative detoxification mechanisms in mice are at least equal to GLO1 and because of the so far 
determined positive side effect even superior. Interestingly, in C. elegans it has been shown recently, 
that mildly elevated MG levels leads to an extended lifespan [Ravichandran et al. 2018] and in D. 
melanogaster, it has been found that in the absent of GLO1 the lifespan is increased [Moraru et al. 
2018]. Data from our study indicating furthermore an increased natural survival in GLO1-/- mice 
possibly through an up-regulation of a defence cascade of alternative detoxification and antioxidant 
enzymes.  
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Altogether, the data of this study implies that, at least with respect to the GLO1 system, lower 
organisms are no suitable model organisms to address the detoxification of MG. Especially the ability 
to enter dauer stages is a critical point in respect to the comparison of C. elegans to humans. 
Whether the data obtained from the mouse model can be transferred to humans needs further 
investigations.  
Why the importance of GLO1 differs massively between the different organisms has still to be 
investigated. A possible explanation might be a change in nutrition and environmental factors, 
resulting in the production of toxic metabolites such as ROS and RCS. Throughout the evolution, the 
increasing complexity of organisms is accompanied by a more complex energy metabolism to ensure 
energy production and healthiness even under unfavourable conditions. S. cerevisiae and C. elegans 
can handle unfavourable conditions by entering rescue stages. The energy metabolism of zebrafishes 
depends on the surrounding temperature. Therefore, they might have evolved other mechanisms as 
compared to warm-blooded organisms. For D. melanogaster, the eggs will only hatch if a food source 
is present. Therefore, changes in energy metabolism are probably limited due to this fact. For mice 
and subsequently also for humans, they have to maintain their energy metabolism and body 
temperature to ensure wellbeing. While fasting by itself will at some point be negative for the 
wellbeing, the food intake afterwards will cause an elevated energy flux and results possibly in the 
production of toxic metabolites. But subsequently, nature has evolved mechanisms, which enables 
mammals to handle negative consequences from elevated energy flux as seen for the alternative 
detoxification mechanisms and the antioxidative capacity in the absence of GLO1.  
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5. Summary 
 
The generation of methylglyoxal-derived advanced glycation end products plays an important role in 
the development of diabetes and late complications. Detoxification of methylglyoxal by glyoxalase 1 
is therefore a key element in the context of dicarbonyl-induced damage in patients suffering from 
diabetes. This assumption was based on findings in simple organisms such as S. cerevisiae and C. 
elegans. Recent findings in D. melanogaster, zebrafish and murine cell lines indicate that glyoxalase 1 
is less significant than in higher organisms. It has been shown that the loss of glyoxalase 1 is 
compensated by increased aldo-keto-reductase and aldehyde dehydrogenase activity. Therefore, the 
major aim of this study was to address potential differences in various organisms regarding their 
dependency on glyoxalase 1 and the determination of physiological consequences of the loss of 
glyoxalase 1.  
Glyoxalase 1-deficient S. cerevisiae and C. elegans accumulate more methylglyoxal, the proliferation 
rate and egg laying rate is decreased and they are sensitive to cellular stress induced by other toxins. 
In zebrafish, MG is mildly elevated, but interestingly they show a decreased sensitivity in part 
towards toxins compared to wild-type animals. Furthermore, in three glyoxalase 1-deficient murine 
cell lines, methylglyoxal is not elevated and they tolerate xenobiotics such as toxins or UV-C radiation 
in a cell and toxin-specific manner possibly through an up-regulation of compensatory enzymes. In 
vivo data reveal furthermore the up-regulation of antioxidant enzymes when glyoxalase is absent, 
subsequently correlating with an elevated natural survival in GLO1-/- mice.  
Complex organisms are less dependent on glyoxalase 1 and less prone to damage despite the loss of 
glyoxalase 1 than expected. In glyoxalase 1-deficient cells and mice, the phenotype even shows a 
protective character. Therefore, the data from this study suggests that the loss of glyoxalase 1 has 
less severe effects on complex organisms than expected and might even lead to an advantage on 
survival through the activation of antioxidant enzymes. The clinical relevance of glyoxalase 1 and 
possible compensatory pathways on the development of late complications in different organs has to 
be addressed in future studies.  
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6. Zusammenfassung 
 
Der während der Glykolyse gebildete toxische Metabolit Methylglyoxal beeinflusst die Entwicklung 
und Progression von diabetischen Spätfolgen. Daher kommt dem Abbau von Methylglyoxal über das 
Glyoxalase-System im Organismus eine wichtige Rolle zu. Die ersten Untersuchungen von Glyoxalase 
1, der wichtigsten Komponente des Gyloxalase-Systems, wurden in einfachen Organismen wie S. 
cerevisiae und C. elegans durchgeführt. Es wurde ermittelt, dass Glyoxalase 1 in diesen Organismen 
das wichtigstes Entgiftungsenzym für Methylgloyxal darstellt. Neuere Daten in höher-entwickelten 
Organismen wie D. melanogaster, Zebrafisch und in murinen Zelllinien weisen darauf hin, dass 
Glyoxalase 1 im Laufe der Evolution an Bedeutung verliert, da ein Verlust der Glyoxalse 1 in murinen 
Schwann-Zellen und in Glyoxalse 1-defizienten Mäusen durch alternative Mechanismen kompensiert 
werden kann.  
Ziel der vorliegenden Studie war es, potentielle Unterschiede in verschiedenen Modellorganismen in 
Bezug auf deren Glyoxalase 1-Abhängigkeit zur Entgiftung und anschließend die daraus 
resultierenden physiologischen Konsequenzen zu erforschen. Glyoxalase 1-defiziente Modelle von S. 
cerevisiae und C. elegans weisen eine erhöhte Akkumulation von Methylglyoxal auf. Zudem sind 
einfache Organismen in ihrer Proliferation und Fertilität eingeschränkt, sowie sensitiver gegenüber 
anderen toxischen Substanzen. In Glyoxalase 1-defizienten Zebrafischen konnte eine nur leicht 
erhöhte Akkumulation von Methylglyoxal festgestellt werden. Überraschenderweise reagierten diese 
Tiere teilweise toleranter auf die Behandlung mit toxischen Substanzen als Wildtyp-Tiere. Zudem 
konnte gezeigt werden, dass Methylglyoxal in drei murinen Glyoxalase 1-defizienten Zelllinien nicht 
erhöht ist. Diese Zellen wiesen darüber hinaus eine Resistenz gegenüber anderen toxischen 
Substanzen und UV-C-Strahlung auf. Ein Grund für die erhöhte Toleranz könnte die erhöhte Aktivität 
von Aldo-Keto-Reduktasen und Aldehyde-Dehydrogenasen sein, die außer Methylglyoxal weitere 
toxische Substanzen entgiften können. Zudem wird die Abwehr in Glyoxalase 1-defizienten Mäusen 
durch die Aktivierung von Antioxidantien verstärkt. Dies führt vermutlich in Glyoxalase 1-defizienten 
Mäusen zu einer gesteigerten Lebenserwartung.  
Säugetiere scheinen demnach weniger abhängig von Glyoxalase 1 als erwartet. Der Verlust der 
Glyoxalase 1 hat einen protektiven Charakter, indem mehrere Schutzmechanismen gegen 
verschiedene Substanzen aktiviert werden. Unsere Daten lassen demnach einen Vorteil vermuten, 
wenn Glyoxalase 1 nicht mehr vorhanden ist. Die Natur hat im Laufe der Evolution mehrere parallele 
Reaktionswege entwickelt, um komplexe Organismen vor schädlichen Umwelteinflüssen zu schützen 
und den Verlust eines einstmaligen wichtigen Enzyms zu kompensieren.  
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